Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GeneDx Holdings Corp.WGS · Entity 1634 | Former CAO | July 01, 2022 | May 31, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GeneDx Holdings Corp.
Report date July 01, 2022 · Filed May 31, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 43,040 |
Ending reported balance
After 2022-08-12 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2022-07-01 · Exercise / conversion · Acquired 5,139 · Balance 37,246 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Row 2 · 2022-07-05 · Sale · Disposed 1,497 · Balance 35,749 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.215 to $1.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2022-08-10 · Exercise / conversion · Acquired 10,457 · Balance 46,206 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Row 4 · 2022-08-12 · Sale · Disposed 3,166 · Balance 43,040 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 77,097 |
Reported balance
After 2022-07-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-07-01 · Exercise / conversion · Disposed 5,139 · Balance 77,097 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4: 6.25% of the total shares underlying the restricted stock units vest in quarterly installments beginning on July 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 115,037 |
Reported balance
After 2022-08-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-08-10 · Exercise / conversion · Disposed 10,457 · Balance 115,037 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F5: 1/16th of the total shares vested beginning on October 25, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on May 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.215 to $1.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: 6.25% of the total shares underlying the restricted stock units vest in quarterly installments beginning on July 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F5: 1/16th of the total shares vested beginning on October 25, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on May 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2022 Filed May 31, 2023 20:17 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 3,166 | $2.17 | $6,870.22 |
DisclosureSEC source: 0001209191-23-033108 · doc4.xml · nonDerivative · entry 4 Assad Shawn · CIK 0001873887 · Former CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,040 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| August 10, 2022 Filed May 31, 2023 20:17 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 10,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033108 · doc4.xml · derivative · entry 6 Assad Shawn · CIK 0001873887 · Former CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,037 Underlying: Class A Common Stock · 10,457 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F5 · derivative.exercise_date: 1/16th of the total shares vested beginning on October 25, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on May 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F5 · derivative.expiration_date: 1/16th of the total shares vested beginning on October 25, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on May 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| August 10, 2022 Filed May 31, 2023 20:17 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 10,457 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-033108 · doc4.xml · nonDerivative · entry 3 Assad Shawn · CIK 0001873887 · Former CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| July 05, 2022 Filed May 31, 2023 20:17 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 1,497 | $1.32 | $1,974.09 |
DisclosureSEC source: 0001209191-23-033108 · doc4.xml · nonDerivative · entry 2 Assad Shawn · CIK 0001873887 · Former CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,749 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.215 to $1.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2022 Filed May 31, 2023 20:17 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 5,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033108 · doc4.xml · derivative · entry 5 Assad Shawn · CIK 0001873887 · Former CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,097 Underlying: Class A Common Stock · 5,139 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% of the total shares underlying the restricted stock units vest in quarterly installments beginning on July 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% of the total shares underlying the restricted stock units vest in quarterly installments beginning on July 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| July 01, 2022 Filed May 31, 2023 20:17 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 5,139 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-033108 · doc4.xml · nonDerivative · entry 1 Assad Shawn · CIK 0001873887 · Former CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| May 11, 2022 Filed May 13, 2022 00:27 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 3,128 | $1.75 | $5,475.25 |
DisclosureSEC source: 0001209191-22-028698 · doc4.xml · nonDerivative · entry 2 Assad Shawn · CIK 0001873887 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,107 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:27 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 10,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028698 · doc4.xml · derivative · entry 3 Assad Shawn · CIK 0001873887 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,494 Underlying: Class A Common Stock · 10,457 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 1/16th of the total shares vested beginning on October 25, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on May 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 1/16th of the total shares vested beginning on October 25, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on May 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:27 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 10,457 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-028698 · doc4.xml · nonDerivative · entry 1 Assad Shawn · CIK 0001873887 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 21:18 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 82,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023521 · doc4.xml · derivative · entry 2 Assad Shawn · CIK 0001873887 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,236 Underlying: Class A Common Stock · 82,236 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F1 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on April 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F1 · derivative.expiration_date: 6.25% vest in quarterly installments over the four-year period commencing on April 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 21:18 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantEmployee Stock Option (Right to Buy) · Derivative | 142,772 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0001209191-22-023521 · doc4.xml · derivative · entry 1 Assad Shawn · CIK 0001873887 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,772 Underlying: Class A Common Stock · 142,772 shares Expires 2032-04-03 F1 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on April 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 01:44 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 3,647 | $3.64 | $13,275.08 |
DisclosureSEC source: 0001209191-22-009575 · doc4.xml · nonDerivative · entry 2 Assad Shawn · CIK 0001873887 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,777 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.64 to $3.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 01:44 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 10,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009575 · doc4.xml · derivative · entry 3 Assad Shawn · CIK 0001873887 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,951 Underlying: Class A Common Stock · 10,457 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 1/16th of the total shares vested beginning on October 25, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on May 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 1/16th of the total shares vested beginning on October 25, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on May 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 01:44 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 10,457 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-009575 · doc4.xml · nonDerivative · entry 1 Assad Shawn · CIK 0001873887 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 00:01 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Tax withholdingClass A Common Stock | 82 | $5.52 | $452.64 |
DisclosureSEC source: 0001209191-21-067990 · doc4.xml · nonDerivative · entry 2 Assad Shawn · CIK 0001873887 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,967 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover certain tax obligation in connection with the stock bonus granted to the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.51 to $5.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 00:01 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantClass A Common Stock | 249 | $6.05 | $1,506.45 |
DisclosureSEC source: 0001209191-21-067990 · doc4.xml · nonDerivative · entry 1 Assad Shawn · CIK 0001873887 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,049 F1 · shares: The indicated shares were issued to Reporting Person as a stock bonus in connection with the elimination of Issuer's sabbatical leave program, in which all employees of Issuer hired on or before June 30, 2021 were provided an opportunity to receive a stock bonus in lieu of their continued eligibility to take sabbatical leave. The stock bonus was fully vested as of the date of issuance. Read SEC document |
| November 10, 2021 Filed Nov 15, 2021 22:35 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 10,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-064519 · doc4.xml · derivative · entry 3 Assad Shawn · CIK 0001873887 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,408 Underlying: Class A Common Stock · 10,457 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 1/16th of the total shares vested on October 25, 2021 and November 10, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on May 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: 1/16th of the total shares vested on October 25, 2021 and November 10, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on May 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| November 10, 2021 Filed Nov 15, 2021 22:35 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 3,114 | $7.87 | $24,507.18 |
DisclosureSEC source: 0001209191-21-064519 · doc4.xml · nonDerivative · entry 2 Assad Shawn · CIK 0001873887 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,800 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| November 10, 2021 Filed Nov 15, 2021 22:35 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 10,457 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-064519 · doc4.xml · nonDerivative · entry 1 Assad Shawn · CIK 0001873887 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| October 25, 2021 Filed Nov 3, 2021 00:27 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 10,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-062556 · doc4.xml · derivative · entry 2 Assad Shawn · CIK 0001873887 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,865 Underlying: Class A Common Stock · 10,457 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 1/16th of the total shares vested on October 25, 2021 and November 10, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on May 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F2 · derivative.expiration_date: 1/16th of the total shares vested on October 25, 2021 and November 10, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on May 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| October 25, 2021 Filed Nov 3, 2021 00:27 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 10,457 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-062556 · doc4.xml · nonDerivative · entry 1 Assad Shawn · CIK 0001873887 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| October 01, 2021 Filed Oct 6, 2021 01:47 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 167,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059760 · doc4.xml · derivative · entry 2 Assad Shawn · CIK 0001873887 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,322 Underlying: Class A Common Stock · 167,322 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F1 · derivative.exercise_date: 1/16th of the total shares vest on October 25, 2021 and November 10, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on May 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F1 · derivative.expiration_date: 1/16th of the total shares vest on October 25, 2021 and November 10, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on May 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| October 01, 2021 Filed Oct 6, 2021 01:47 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantEmployee Stock Option (Right to Buy) · Derivative | 96,830 | $0.00 Strike: $7.62 | $0.00 |
DisclosureSEC source: 0001209191-21-059760 · doc4.xml · derivative · entry 1 Assad Shawn · CIK 0001873887 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,830 Underlying: Class A Common Stock · 96,830 shares Expires 2031-09-30 F1 · derivative.exercise_date: 1/16th of the total shares vest on October 25, 2021 and November 10, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on May 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| October 01, 2021 Filed Oct 7, 2021 01:11 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 34,776 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059876 · doc4.xml · derivative · entry 1 Assad Shawn · CIK 0001873887 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,776 Underlying: Class A Common Stock · 34,776 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 25% of the total shares vest on October 1, 2022, and thereafter vests as to 75% of the total shares underlying the award in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F2 · derivative.expiration_date: 25% of the total shares vest on October 1, 2022, and thereafter vests as to 75% of the total shares underlying the award in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| October 01, 2021 Filed Nov 3, 2021 00:29 UTC Amendment | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 34,776 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-062559 · doc4a.xml · derivative · entry 1 Assad Shawn · CIK 0001873887 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,776 Underlying: Class A Common Stock · 34,776 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: This Form 4 is being amended to correct the vesting schedule as to 25% of the total shares vest on October 1, 2023, and thereafter as to 75% of the total shares underlying the award in quarterly installments until fully vested on October 1, 2026, subject to the Reporting Person's continued service to the Issuer on each vesting date. F2 · derivative.expiration_date: This Form 4 is being amended to correct the vesting schedule as to 25% of the total shares vest on October 1, 2023, and thereafter as to 75% of the total shares underlying the award in quarterly installments until fully vested on October 1, 2026, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.